CareDx (CDNA) Expected to Announce Earnings on Tuesday

CareDx (NASDAQ:CDNA) is anticipated to announce its Q3 2025 results after the market closes on Tuesday, November 4th. Analysts expect the company to announce earnings of $0.13 per share and revenue of $95.25 million for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Tuesday, November 4, 2025 at 4:30 PM ET.

CareDx (NASDAQ:CDNA) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.28). CareDx had a return on equity of 18.03% and a net margin of 17.97%.The business had revenue of $90.51 million for the quarter, compared to analyst estimates of $90.72 million. During the same period last year, the firm posted $0.25 EPS. CareDx’s quarterly revenue was down 6.1% on a year-over-year basis. On average, analysts expect CareDx to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

CareDx Stock Up 3.7%

Shares of CDNA stock opened at $15.00 on Friday. The business has a fifty day simple moving average of $14.32 and a 200 day simple moving average of $15.66. The company has a market cap of $798.41 million, a P/E ratio of 14.71 and a beta of 2.37. CareDx has a twelve month low of $10.96 and a twelve month high of $26.37.

Institutional Trading of CareDx

Institutional investors have recently modified their holdings of the business. Bamco Inc. NY increased its holdings in CareDx by 11.2% in the second quarter. Bamco Inc. NY now owns 2,435,657 shares of the company’s stock valued at $47,593,000 after purchasing an additional 245,651 shares during the period. Goldman Sachs Group Inc. grew its position in shares of CareDx by 18.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,110,014 shares of the company’s stock valued at $19,703,000 after buying an additional 170,504 shares during the last quarter. Meridiem Capital Partners LP acquired a new stake in shares of CareDx in the second quarter valued at about $2,411,000. First Trust Advisors LP bought a new position in shares of CareDx during the second quarter worth about $1,822,000. Finally, Lazard Asset Management LLC lifted its stake in shares of CareDx by 642.8% in the second quarter. Lazard Asset Management LLC now owns 102,740 shares of the company’s stock worth $2,006,000 after acquiring an additional 88,909 shares during the period.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the stock. Craig Hallum reduced their price target on shares of CareDx from $40.00 to $26.00 and set a “buy” rating on the stock in a research note on Friday, July 18th. William Blair started coverage on shares of CareDx in a research report on Tuesday, August 26th. They issued a “market perform” rating on the stock. Wall Street Zen cut shares of CareDx from a “hold” rating to a “sell” rating in a research note on Tuesday, October 28th. Weiss Ratings reiterated a “sell (d+)” rating on shares of CareDx in a report on Wednesday, October 8th. Finally, BTIG Research reissued a “buy” rating and set a $22.00 price objective on shares of CareDx in a report on Tuesday, September 23rd. Four research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $25.50.

CareDx Company Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.